Like most websites The Cannabis Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Research & Development Medical research, Pharmaceutical

THC for Tourette’s

THX-TS01, a drug candidate combining synthetic tetrahydrocannabinol (THC) and palmitoylethanolamide (PEA) into a single dose for the treatment of Tourette’s syndrome. A preliminary clinical trial is set to finish soon.

Pharmaceutical company Therapix Biosciences Ltd are partnering with drug delivery specialists Catalent Pharma Solutions. The Catalent team will develop, formulate, and manufacture the novel softgel drug candidate at their Florida facility.

Previous research has demonstrated that THC can reduce the physical and vocal tics that characterize Tourette’s Syndrome (1). Therapix state that their objective is to manufacture an effective, FDA-approved medication for reduction of these symptoms.

A press release from Therapix states, “[PEA] may indirectly stimulate the cannabinoid receptors by potentiating their affinity for a receptor, or by inhibiting their metabolic degradation”, which could increase the uptake – and efficacy – of the THC. This example of two endocannabinoid system actors working in synergy was described as the “Entourage Effect” by pioneering organic chemist Raphael Mechoulam. Softgels are used to formulate poorly water-soluble drugs (like cannabinoids) into tablet form.

What next?
The drug combination is currently being tested in a proof-of-concept trial in a small group of Tourette’s sufferers. A separate drug development program (THX-ULD01) aims to treat mild cognitive impairment, a precursor to dementia.

KR Müller-Vahl, “Cannabinoids reduce symptoms of Tourette’s syndrome”, Expert Opin Pharmacother, 4, 1717-1725 (2003).

Receive content, products, events as well as relevant industry updates from The Cannabis Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Cannabis Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Cannabis Scientist magazine